Tuesday, July 21, 2026

Intelligence · Patents

Patents expiring in 2032

Annual patent cliff calendar for 2032 — US pharmaceutical patents by expiration date.

Patents
37

Quick answer

37 indexed pharmaceutical patents have expiration dates in 2032. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8105626

    Granules containing acid-unstable chemical in large amount

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 31 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 8106022

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 31 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 8114900

    Amorphous carvedilol dihydrogen phosphate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 8124644

    Carvedilol phosphate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Feb 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 8148356

    Acetylcysteine composition and uses therefor

    Cumberland Pharmaceuticals Inc. · Granted Tue Apr 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 8158601

    Lipid formulation

    Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 8158146

    Stable combinations of amlodipine besylate and benazepril hydrochloride

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 8163960

    Process for preparing and drying solid rasagiline base

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 8163309

    Starch foam microparticles

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Apr 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 8163902

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Tue Apr 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 8168775

    Compositions and methods for inhibiting expression of transthyretin

    Alnylam Pharmaceuticals, Inc. · Granted Tue May 01 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 8173158

    Methods of treating gastrointestinal disorders independent of the intake of food

    Takeda Pharmaceuticals U.S.A., Inc. · Granted Tue May 08 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 8178127

    Stable laquinimod preparations

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 8182842

    Physico-chemical-managed killing of penicillin-resistant static and growing gram-positive and gram-negative vegetative bacteria

    The United States of America as represented by the Administrator of the National Aeronautics and Space Administration · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 8183373

    Solid state forms of sitagliptin salts

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 8183274

    Treatment of hyperproliferative disorders with diarylhydantoin compounds

    The Regents of the University of California · Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 8188067

    Formulations of 6-mercaptopurine

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 8193204

    Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use

    LEXICON PHARMACEUTICALS, INC. · Granted Tue Jun 05 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 8198242

    Variants of C-type natriuretic peptide

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Jun 12 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 07 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 8203005

    Manufacturing process for enantiomerically pure 8-aryloctanoic acids as Aliskiren

    Carbo Design LLC · Granted Tue Jun 19 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 14 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  21. US 8202517

    Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

    HALOZYME, INC. · Granted Tue Jun 19 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 14 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  22. US 8211889

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Tue Jul 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 28 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  23. US 8211464

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Supernus Pharmaceuticals, Inc. · Granted Tue Jul 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 28 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  24. US 8217156

    Solid forms of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and methods of their use

    LEXICON PHARMACEUTICALS, INC. · Granted Tue Jul 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  25. US 8222222

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  26. US 8242305

    Process to prepare treprostinil, the active ingredient in remodulin

    United Therapeutics Corporation · Granted Tue Aug 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  27. US 8263122

    Wet granulation using a water sequestering agent

    Rigel Pharmaceuticals, Inc. · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  28. US 8288342

    Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate

    TEVA WOMEN'S HEALTH, INC. · Granted Tue Oct 16 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  29. US 8298580

    Sustained-release formulations of topiramate

    Supernus Pharmaceuticals, Inc. · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  30. US 8298576

    Sustained-release formulations of topiramate

    Supernus Pharmaceuticals, Inc. · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  31. US 8318817

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    The Regents of the University of California · Granted Tue Nov 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  32. US 8323671

    Prolyl hydroxylase inhibitors and methods of use

    Akebia Therapeutics, Inc. · Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  33. US 8324242

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  34. US 8324192

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    The Regents of the University of California · Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  35. US 8329696

    Solid state forms of sitagliptin salts

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  36. US 8334409

    Process for purifying rasagiline base

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  37. US 8343952

    Prolyl hydroxylase inhibitors and methods of use

    Akebia Therapeutics, Inc. · Granted Tue Jan 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2032?

37 published patents in our USPTO index have expiration dates falling in calendar year 2032.